JP Morgan Chase’s Akcea Therapeutics Inc AKCA Stock Holding History

JP Morgan Chase’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-35,300	Closed	-$543K	–	6021
2019 Q3	$543K	Sell	35,300 -2,500	-7%	-$53.3K	﹤0.01%	4136
2019 Q2	$874K	Buy	37,800 +12,800	+51%	+$316K	﹤0.01%	3943
2019 Q1	$708K	Sell	25,000 -5,000	-17%	-$146K	﹤0.01%	4005
2018 Q4	$904K	Buy	30,000 +7,000	+30%	+$196K	﹤0.01%	3807
2018 Q3	$805K	Sell	23,000 -31,000	-57%	-$938K	﹤0.01%	4037
2018 Q2	$1.28M	Buy	+54,000	New	+$1.29M	﹤0.01%	3685

JP Morgan Chase's AKCA Position: Q4 2020 in Review

JP Morgan Chase sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 6,134 shares — an estimated $111K sold.

JP Morgan Chase first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $152K in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

JP Morgan Chase reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
JP Morgan Chase sold 6,134 Akcea Therapeutics Inc shares in Q4 2020, an estimated $111K.
JP Morgan Chase first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
JP Morgan Chase's Akcea Therapeutics Inc position peaked at $152K in Q3 2018.
0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on JP Morgan Chase's 13F filing for Q4 2020, filed 11 Feb 2021.